US Gestational Diabetes Market Overview
As per MRFR analysis, the US Gestational Diabetes Market Size was estimated at 1.81 (USD Billion) in 2023. The US Gestational Diabetes Market Industry is expected to grow from 1.95(USD Billion) in 2024 to 5.07 (USD Billion) by 2035. The US Gestational Diabetes Market CAGR (growth rate) is expected to be around 9.075% during the forecast period (2025 - 2035).
The US Gestational Diabetes Market is witnessing several important trends driven by increasing awareness around maternal health. As more women are informed about the potential risks associated with gestational diabetes, there is a growing demand for diagnostics and monitoring solutions. The rise in obesity rates among pregnant women has also been identified as a key market driver, leading to a heightened focus on prenatal care and lifestyle management. Moreover, healthcare policies in the US are increasingly supporting improved access to screenings and treatments, which further drives market growth.
Opportunities lie in the development of advanced technologies and digital health solutions, including mobile applications for blood sugar monitoring and telehealth consultations. With the advent of new technologies, healthcare providers can offer more personalized care to their patients, which could improve outcomes for mothers and infants alike. Additionally, there is an emerging market for dietary supplements and educational programs targeting nutrition and lifestyle changes during pregnancy, aiming to prevent gestational diabetes or manage its symptoms effectively.
Trends in recent times also indicate a stronger emphasis on interdisciplinary care, where obstetricians, dietitians, and endocrinologists collaborate to provide comprehensive management plans. Increased focus on patient education has sparked a shift toward proactive measures for managing gestational diabetes, ensuring that expecting mothers have access to resources that empower them to take charge of their health.
Furthermore, policies promoting healthier food options in schools and communities are gaining traction, which can also indirectly influence gestational diabetes outcomes among future generations, highlighting an ongoing commitment to addressing this important public health concern in the US.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rise in obesity rates among women of reproductive age is a significant driver of the US Gestational Diabetes Market Industry. According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence among women of childbearing age in the United States is approximately 38%. This alarming figure indicates not only a direct correlation with the likelihood of developing gestational diabetes but also highlights a broader public health concern.
As more women enter pregnancy with obesity, the risk of gestational diabetes increases markedly, necessitating better screening and management solutions. Major health organizations, such as the American Diabetes Association, continue to advocate for higher awareness and intervention strategies in managing gestational diabetes, which directly drives market growth by requiring more innovative treatment options, monitoring devices, and educational resources.
The increasing focus on prenatal care and early screening initiatives for gestational diabetes is transforming the landscape of the US Gestational Diabetes Market Industry. The American College of Obstetricians and Gynecologists recommends routine screening for all pregnant women, emphasizing the need for early detection to mitigate risks to both mother and child. Reports indicate that approximately 7-10% of pregnant women are diagnosed with gestational diabetes in the U.S. annually.
As awareness spreads through public health campaigns, more women are being screened, leading to higher demand for diagnostic tools and treatment options. This proactive approach reflects a significant market opportunity, encouraging companies to innovate and improve on existing products.
Recent technological advancements in diabetes management tools are another critical driver of the US Gestational Diabetes Market Industry. The adoption of continuous glucose monitoring systems has surged, providing expectant mothers with real-time data on glucose levels, thus improving management of gestational diabetes. According to the Food and Drug Administration (FDA), there has been a substantial rise in the number of approved devices reflecting innovation in this sphere.
Enhanced features such as mobile applications that track blood sugar levels also play a pivotal role in facilitating better self-management among expectant mothers. These developments not only improve patient outcomes but also encourage manufacturers to invest in Research and Development to meet the growing demand.
The US Gestational Diabetes Market encompasses various diagnosis types that play a critical role in the identification and management of gestational diabetes among pregnant women. Among these, the Oral Glucose Tolerance Test (OGTT) stands out as a standard method due to its ability to provide a comprehensive assessment of insulin response and glucose metabolism. This test typically requires patients to fast beforehand and then undergo a series of blood draws after consuming a sugary drink, making it an effective tool for diagnosing gestational diabetes.
The Fasting Blood Sugar Test remains popular for its simplicity and convenience, as it measures blood sugar levels first thing in the morning, helping to identify abnormal glucose levels early in the pregnancy. Meanwhile, the Random Blood Sugar Test offers a quick diagnostic option that can be performed at any time, assessing glucose levels in real-time regardless of recent food intake. This flexibility can be particularly beneficial in settings where time is crucial.
Lastly, the Hemoglobin A1c Test is increasingly recognized for its ability to provide an overview of average blood sugar levels over the past two to three months, although it is less commonly used in pregnancy due to specific guidelines. Overall, the US Gestational Diabetes Market segmentation by diagnosis type reflects the diverse approaches in the management of this condition, with each method having its own unique advantages and relevance in ensuring the health of both mothers and their babies.
The specific emphasis on accurate diagnosis is essential, given that appropriate interventions can significantly reduce the risks of complications related to gestational diabetes. The choice of diagnostic method often depends on factors such as availability, patient preference, and clinical guidelines, influencing overall market dynamics and driving advancements in technology and patient management strategies within the industry. As healthcare providers continue to learn more about gestational diabetes, improvements in these diagnostic techniques are expected to evolve, contributing to better patient outcomes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment Type segment of the US Gestational Diabetes Market focuses on various methods employed to manage the condition effectively. Dietary Changes play a crucial role, as proper nutrition helps control blood sugar levels, promoting better outcomes for both mothers and infants. Insulin Therapy is significant for those who cannot manage their glucose levels with diet alone; it provides a direct method for controlling blood sugar.
Oral Medications are also utilized, though their application can be limited during pregnancy; nonetheless, they represent an important option for specific patient needs. Physical Activity is vital, as structured exercise improves insulin sensitivity and contributes to overall well-being during pregnancy. The interplay between these treatment types highlights the multifaceted approach required to address gestational diabetes, emphasizing the necessity for personalized care plans.
Trends suggest that both healthcare providers and patients are increasingly recognizing the significance of holistic treatment strategies, promoting the importance of lifestyle modifications alongside pharmacological interventions. With rising awareness of gestational diabetes implications, growth in this segment is expected, driven by both emerging research and an expanding recognition of maternal health's importance in the US healthcare industry.
The US Gestational Diabetes Market is significantly influenced by various risk factors, which play a crucial role in understanding the evolving dynamics of the market. Among these, obesity is a prominent factor, as it has consistently linked to higher chances of developing gestational diabetes, making it an essential focus area for healthcare professionals and policy makers. Family history represents another significant risk factor; having close relatives with diabetes increases susceptibility, highlighting the need for targeted awareness campaigns aimed at at-risk populations.
Age also stands as an important consideration, with older pregnant women facing elevated risks. Previous gestational diabetes is a critical aspect too, as women with a history of the condition have a much higher likelihood of experiencing it again in future pregnancies. The interplay of these risk factors not only affects individual health outcomes but also informs public health strategies and clinical practices aimed at managing and reducing the incidence of gestational diabetes. Understanding these risk factors helps in the development of preventive measures and aligns with the broader goals of enhancing maternal and fetal health in the US.
The US Gestational Diabetes Market showcases significant segmentation based on Patient Age, which plays a crucial role in understanding the demographics affected by this condition. Among the distinct age groups, Teenagers represent a growing prevalence, often influenced by lifestyle factors and rising obesity rates. This subset is crucial as early intervention can significantly impact their long-term health outcomes.
Adults, particularly in the 25-35 age range, represent the majority holding within the market due to increased pregnancies among this demographic, driving awareness and screening practices for gestational diabetes. The Elderly population, while not the primary focus, still necessitates attention as delayed pregnancies become more common; their health complications could exacerbate gestational diabetes conditions.
The market growth hinges on these dynamics, with targeted awareness campaigns and healthcare initiatives necessary to address the age-related risks associated with gestational diabetes. Additionally, there are opportunities emerging with advancements in technology and personalized healthcare that cater specifically to the unique needs of each age group, ensuring better management and outcomes in the US Gestational Diabetes Market.
The US Gestational Diabetes Market has been experiencing significant growth, driven by a rising awareness of maternal health and the increasing prevalence of gestational diabetes among pregnant women. Various factors, including lifestyle changes, genetic predispositions, and an expanding aging population, have contributed to the rising incidence of this condition, prompting the demand for effective monitoring and treatment solutions. Competitive dynamics within this market reflect the presence of notable players who are continuously engaged in enhancing their product portfolios, improving patient care, and strategically collaborating to gain market share.
Companies are focusing on innovations and technological advancements to streamline diabetes management and make diagnostic processes more efficient. The competitive landscape is characterized by the presence of established brands alongside emerging players, all vying to provide comprehensive solutions tailored to the specific needs of women experiencing gestational diabetes.
The US Gestational Diabetes Market has seen significant developments recently, particularly in the context of rising awareness and advancements in technology. Companies such as Abbott Laboratories and Roche Holding are increasingly focusing on the enhancement of diabetes management solutions, with a push toward digital health tools and continuous glucose monitors. In terms of market dynamics, the valuation of the market is experiencing growth due to the increasing prevalence of gestational diabetes and the introduction of new diagnostic tools.
Notably, Quidel Corporation and Medtronic have made strides in expanding their product lines to address this growing need. In recent months, there have been reports of mergers and acquisitions affecting key players; for instance, Eli Lilly and Company’s acquisition of a small diabetes-focused firm was acknowledged in July 2023, reflecting a focused strategy on addressing gestational diabetes. Another significant move was made by Johnson and Johnson, which launched new clinical guidelines in February 2023 to improve management protocols.
The collaboration between Dexcom and Ascensia Diabetes Care on integrated devices aims to streamline patient care, highlighting the industry's commitment to innovation and patient-centric solutions in the US market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.81(USD Billion) |
| MARKET SIZE 2024 | 1.95(USD Billion) |
| MARKET SIZE 2035 | 5.07(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.075% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Quidel Corporation, Roche Holding, Medtronic, Abbott Laboratories, Eli Lilly and Company, Dexcom, Ascensia Diabetes Care, Thermo Fisher Scientific, Abbvie, AmerisourceBergen, GlucoWise, Sanofi, Johnson and Johnson, Becton Dickinson, Freenome |
| SEGMENTS COVERED | Diagnosis Type, Treatment Type, Risk Factor, Patient Age |
| KEY MARKET OPPORTUNITIES | Telehealth diabetes management solutions, Mobile app for tracking glucose levels, Nutritional counseling and meal planning, Enhanced diabetes screening protocols, Personalized patient education programs |
| KEY MARKET DYNAMICS | rising prevalence of gestational diabetes, increasing awareness and screening, advancements in continuous glucose monitoring, focus on dietary management and lifestyle, growing investment in digital health solutions |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Gestational Diabetes Market is expected to be valued at approximately 1.95 USD Billion in 2024.
By 2035, the US Gestational Diabetes Market is projected to reach a value of around 5.07 USD Billion.
The market is anticipated to grow at a compound annual growth rate (CAGR) of 9.075% from 2025 to 2035.
The Oral Glucose Tolerance Test is expected to dominate, with a projected market value of 2.0 USD Billion by 2035.
The Fasting Blood Sugar Test is projected to be valued at 1.4 USD Billion in 2035.
Key players in the market include Quidel Corporation, Roche Holding, Medtronic, Abbott Laboratories, and Eli Lilly and Company.
By 2035, the market for the Random Blood Sugar Test is expected to reach 1.1 USD Billion.
The Hemoglobin A1c Test segment is projected to grow to a market value of 0.57 USD Billion by 2035.
Driving trends include increasing awareness of gestational diabetes and advancements in diagnostic technologies.
The competitive landscape is expected to evolve with innovations from major players and new entrants focusing on advanced diagnostics.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
